A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer

Study Overview

This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer.

Study Description

Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.


  • IRB Number: 1811442903 (S1706)
  • Research Study Identifier: TX10166
  • Principal Investigator: Richard Zellars, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176